BioCentury | Feb 12, 2021
Deals

Feb. 11 Quick Takes: First day pop for Bioventus; plus venture rounds for Pipeline, Immunai, Sanofi, i2O, AZ’s trimmings, Truveta

...durvalumab is ongoing in the indication. The pharma holds its rights under a deal with Sosei Group Corp....
BioCentury | Feb 2, 2021
Deals

Feb. 1 Quick Takes: Coherus gets rights to Junshi’s PD-1; plus GSK backs newco Adrestia, a seed for Cellino and more

...only then removed under certain conditions to improve the therapeutic window by minimizing on-target, off-tissue toxicity.Sosei...
...with Metrion drug discovery dealSosei Group Corp. (Tokyo:4565) partnered with Metrion Biosciences Ltd. to use Sosei...
...on a single ion channel target for neurology indications involving Metrion’s IP and screening models. Sosei...
BioCentury | Jan 6, 2021
Deals

Jan. 5 Quick Takes: Myriad restructuring; plus ViGeneron-Biogen, Rhythm, Sosei and more

...agonists to SoseiAbbVie Inc. (NYSE:ABBV) has returned rights to muscarinic agonist programs to Sosei Group Corp. (Tokyo:4565). Sosei...
...receptorPCSK1 – Proprotein convertase subtilisin/kexin type 1POMC – Proopiomelanocortin BC Staff HGH-CTP, Lagova, somatrogon (MOD-4023, PF-06836922) Myriad Genetics ViGeneron Biogen Rhythm Pharmaceuticals Sosei Nirmidas...
BioCentury | Dec 22, 2020
Deals

Dec. 21-23 Deals Quick Takes: Cytokinetics regains European rights to heart failure program; plus Boehringer-Epizyme, Vertex-Skyhawk, Lilly-Prevail, GSK-Sosei Heptares, ImmunityBio-NantKwest and more

...million to the deal’s value.GSK obtains rights to Sosei Heptares’ GPR35sThe Sosei Heptares unit of Sosei Group Corp....
...portfolio of preclinical GPR35 agonists to treat inflammatory bowel disease and other immune gastrointestinal disorders. Sosei...
BioCentury | Dec 2, 2020
Regulation

Dec. 1 Quick Takes: broader label for Blueprint; plus Minerva, Biohaven-Sosei, Genetron, PegBio, drug imports

...$1 (26%) to $2.89 on Tuesday.Biohaven, Sosei Heptares in CGRP dealThe Sosei Heptares unit of Sosei Group Corp....
...portfolio of small molecule CGRP receptor antagonists, including preclinical therapy HTL0022562, to treat CGRP-mediated disorders. Sosei...
...a drug shortage. TARGETSCGRP – Calcitonin gene-related peptide BC Staff Genetron Health PegBio Minerva Neurosciences Blueprint Medicines Biohaven Pharmaceutical Holding Co. Ltd. Sosei Group Corp. drug...
BioCentury | Nov 4, 2020
Deals

Novartis vets Jimenez, Fishman thread digital into fabric of new VC firm Aditum, launch Tempero

...anxiety disorders from Sosei Heptares, a unit of Sosei Group Corp....
...mGluR5 negative allosteric modulators (NAMs) licensed from Sosei...
...in a Phase I single-ascending dose study. Sosei...
BioCentury | Oct 13, 2020
Product Development

Data Bytes: coronavirus-targeted small molecules

...preclinical development: Anivive Lifesciences Inc., Cocrystal Pharma Inc. (NASDAQ:COCP), Insilico Medicine Inc., Pardes Biosciences Inc. and Sosei Group Corp....
BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

...Bains as chief business officer. Bains was previously CEO of Sosei Heptares, a unit of Sosei Group Corp....
BioCentury | Sep 10, 2020
Finance

MiNA raises £23M in first venture round 12 years after launch

...By Virginia Li, Associate Editor After financing itself for 12 years via high-net-worth individuals and Sosei...
...from high-net worth individuals and through a £35 million investment from Sosei Group Corp. (Tokyo:4565) in 2017 (see “RNA is for Activation”; “Sosei...
BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

...Cahlen as CEO, effective Nov. 1, to succeed Mats Grahn, who now sits on the board.Sosei Group Corp....
Items per page:
1 - 10 of 427
BioCentury | Feb 12, 2021
Deals

Feb. 11 Quick Takes: First day pop for Bioventus; plus venture rounds for Pipeline, Immunai, Sanofi, i2O, AZ’s trimmings, Truveta

...durvalumab is ongoing in the indication. The pharma holds its rights under a deal with Sosei Group Corp....
BioCentury | Feb 2, 2021
Deals

Feb. 1 Quick Takes: Coherus gets rights to Junshi’s PD-1; plus GSK backs newco Adrestia, a seed for Cellino and more

...only then removed under certain conditions to improve the therapeutic window by minimizing on-target, off-tissue toxicity.Sosei...
...with Metrion drug discovery dealSosei Group Corp. (Tokyo:4565) partnered with Metrion Biosciences Ltd. to use Sosei...
...on a single ion channel target for neurology indications involving Metrion’s IP and screening models. Sosei...
BioCentury | Jan 6, 2021
Deals

Jan. 5 Quick Takes: Myriad restructuring; plus ViGeneron-Biogen, Rhythm, Sosei and more

...agonists to SoseiAbbVie Inc. (NYSE:ABBV) has returned rights to muscarinic agonist programs to Sosei Group Corp. (Tokyo:4565). Sosei...
...receptorPCSK1 – Proprotein convertase subtilisin/kexin type 1POMC – Proopiomelanocortin BC Staff HGH-CTP, Lagova, somatrogon (MOD-4023, PF-06836922) Myriad Genetics ViGeneron Biogen Rhythm Pharmaceuticals Sosei Nirmidas...
BioCentury | Dec 22, 2020
Deals

Dec. 21-23 Deals Quick Takes: Cytokinetics regains European rights to heart failure program; plus Boehringer-Epizyme, Vertex-Skyhawk, Lilly-Prevail, GSK-Sosei Heptares, ImmunityBio-NantKwest and more

...million to the deal’s value.GSK obtains rights to Sosei Heptares’ GPR35sThe Sosei Heptares unit of Sosei Group Corp....
...portfolio of preclinical GPR35 agonists to treat inflammatory bowel disease and other immune gastrointestinal disorders. Sosei...
BioCentury | Dec 2, 2020
Regulation

Dec. 1 Quick Takes: broader label for Blueprint; plus Minerva, Biohaven-Sosei, Genetron, PegBio, drug imports

...$1 (26%) to $2.89 on Tuesday.Biohaven, Sosei Heptares in CGRP dealThe Sosei Heptares unit of Sosei Group Corp....
...portfolio of small molecule CGRP receptor antagonists, including preclinical therapy HTL0022562, to treat CGRP-mediated disorders. Sosei...
...a drug shortage. TARGETSCGRP – Calcitonin gene-related peptide BC Staff Genetron Health PegBio Minerva Neurosciences Blueprint Medicines Biohaven Pharmaceutical Holding Co. Ltd. Sosei Group Corp. drug...
BioCentury | Nov 4, 2020
Deals

Novartis vets Jimenez, Fishman thread digital into fabric of new VC firm Aditum, launch Tempero

...anxiety disorders from Sosei Heptares, a unit of Sosei Group Corp....
...mGluR5 negative allosteric modulators (NAMs) licensed from Sosei...
...in a Phase I single-ascending dose study. Sosei...
BioCentury | Oct 13, 2020
Product Development

Data Bytes: coronavirus-targeted small molecules

...preclinical development: Anivive Lifesciences Inc., Cocrystal Pharma Inc. (NASDAQ:COCP), Insilico Medicine Inc., Pardes Biosciences Inc. and Sosei Group Corp....
BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

...Bains as chief business officer. Bains was previously CEO of Sosei Heptares, a unit of Sosei Group Corp....
BioCentury | Sep 10, 2020
Finance

MiNA raises £23M in first venture round 12 years after launch

...By Virginia Li, Associate Editor After financing itself for 12 years via high-net-worth individuals and Sosei...
...from high-net worth individuals and through a £35 million investment from Sosei Group Corp. (Tokyo:4565) in 2017 (see “RNA is for Activation”; “Sosei...
BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

...Cahlen as CEO, effective Nov. 1, to succeed Mats Grahn, who now sits on the board.Sosei Group Corp....
Items per page:
1 - 10 of 427